Dr. Jacob P. Laubach, MD

Dr. Laubach practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Laubach's NPI, 1922086487, was assigned on January 5, 2006. Dr. Laubach graduated from Duke University School Of Medicine in 1999. Dr. Laubach holds Massachusetts license 236121.

Dr. Laubach's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Laubach's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Laubach is also affiliated with Massachusetts General Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Laubach to 3 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Laubach practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Laubach's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Laubach is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Laubach's licenses on file in 3 states: Massachusetts, New Hampshire and North Carolina.

Dmand AI lists kidney stone disease and parathyroid gland disorder among the conditions Dr. Laubach treats.

CMS data shows 788 Medicare services from Dr. Laubach across 5 procedure codes in 2024, for 462 Medicare patients. Medicare paid $68,029 for them.

CMS counts 462 Medicare patients who saw Dr. Laubach in 2024. The largest group is 65 to 74, with 230 patients. 70% of them have high blood pressure, and 67% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Laubach's median patient age at 72, with 46% women.

In 2024, Dr. Laubach wrote 229 Medicare Part D claims for 91 patients. 51% of them were for generic drugs. CMS names the drug for 163 of them, across 6 drugs with 11 or more claims each, at $1,666,976 in total drug cost. In 2023, CMS named 188 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Laubach for performance year 2024, reported as part of a group. Dr. Laubach accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Laubach as offering telehealth.

Dmand AI links 205 papers to Dr. Laubach, published from 2009 to 2025. 2018 was the busiest year, with 15. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Dexamethasone. Dr. Laubach has published most often in Br J Haematol. Dr. Laubach's most frequent co-authors are Kenneth C. Anderson, MD, Sagar Lonial, MD and Robert Lawrence Schlossman, MD.

Dmand AI links Dr. Laubach to 18 clinical trials, 8 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Bone Diseases. Dana-Farber Cancer Institute sponsors the most, 5. Open Payments lists research payments to Dr. Laubach that name 1 trial.

CMS Open Payments shows 24 general payments to Dr. Laubach from 8 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 44% of the total. Millennium Pharmaceuticals, Inc. paid the most, $16,552. It also lists 7 research payments totaling $8,488 from 2016 to 2024, naming 1 clinical trial.

Dr. Laubach graduated from Duke University School Of Medicine in 1999.

Dr. Laubach is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.